Steven Leichter, MD
Endocrinology, Diabetes & Metabolism · Columbus, GANPI 1548302201
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.6%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 54 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 25.5% of the total. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 903 payments — averaging $47.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$11K
- Sanofi-aventis U.S. LLC$10K
- AbbVie$4K
- Dexcom, Inc.$3K
- Novo Nordisk$2K
- Lilly USA, LLC$2K
- plus $11K from 48 others
Across 2,060 payments — averaging $1481.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1.4M
- Novo Nordisk AS$478K
- Sanofi US Services Inc.$301K
- Boehringer Ingelheim$232K
- Boehringer Ingelheim Pharma GmbH & Co.kg$154K
- Acella Pharmaceuticals, LLC$102K
- plus $418K from 12 others
What the payments were for
- Consulting fees$9,70022%
- Speaking & faculty fees$11,70027%
- Travel & lodging$1,2203%
- Food & beverage$20,18947%
- Education$5051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TZIELD$7,078
- t:slim X2 insulin pump$5,900
- t-slim insulin pump$4,404
- DEXCOM G6 TRANSMITTER$2,057
- iLet Bionic Pancreas$1,220
- Kerendia$689
- t:slim X2 Insulin Pump with Control-IQ$523
- DEXCOM CGM$434
- EVENITY$358
- Korlym$252
- JARDIANCE$249
- RYBELSUS$233
- Ozempic$230
- Wegovy$220
- FreeStyle Lite system$150
- iLet Insulin Infusion Kit Inset$143
- iLet Insulin Infusion Kit Contact Detach$143
- UNITY DIABETES MANAGEMENT SYSTEM$139
- InPen$125
- Imcivree$125
How this compares
$43,314 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 441 | $568,264 |
| OzempicSemaglutide | 269 | $420,653 |
| TymlosAbaloparatide | 91 | $323,433 |
| RybelsusSemaglutide | 148 | $241,502 |
| MounjaroTirzepatide | 147 | $197,311 |
| ForteoTeriparatide | 34 | $181,527 |
| TrulicityDulaglutide | 89 | $117,201 |
| Tresiba Flextouch U-100Insulin Degludec | 155 | $93,385 |
| GenotropinSomatropin | 30 | $83,738 |
| Repatha SureclickEvolocumab | 63 | $71,586 |
| SynjardyEmpagliflozin/Metformin Hcl | 58 | $67,520 |
| JanuviaSitagliptin Phosphate | 43 | $50,285 |
| OmnitropeSomatropin | 37 | $49,220 |
| ProliaDenosumab | 26 | $44,649 |
| FarxigaDapagliflozin Propanediol | 57 | $44,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,387 | $683,765475 claims |
| Boehringer IngelheimJardiance, Synjardy | $881 | $635,784499 claims |
| Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog | $1,631 | $505,394308 claims |
| Radius Health, Inc.Tymlos | $1,214 | $323,43391 claims |
| PfizerGenotropin | $53 | $83,73830 claims |
| MerckJanuvia, Janumet | $138 | $78,87669 claims |
| AmgenProlia | $1,247 | $44,64926 claims |
| AstraZenecaFarxiga | $35 | $44,20157 claims |
| BayerKerendia | $1,359 | $40,56629 claims |
| AbbVieSynthroid | $3,760 | $11,971111 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $111 | $5,994495 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Columbus
- Mallika ThiruppathiColumbus$12K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Barry JohnsMacon$335K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.